Transfemoral Transcatheter Aortic Valve Replacement for Pure Native Aortic Regurgitation: One-Year Outcomes of a Single-center study

Abstract

Abstract Background Evidence about safety and efficacy of transcatheter aortic valve replacement (TAVR) with the Venus A-Valve system (Venus Medtech, Hangzhou, China) remains limited for patients with pure native aortic regurgitation (PNAR).Objectives The single-center study sought to report the one-year clinical outcomes of the Venus A-Valve in the treatment of PNAR.Methods This study was a retrospective analysis of prospectively collected data. Data was from all consecutive patients who had PNAR and underwent TAVR with the Venus A-Valve at three Chinese centers from June 2019 and July 2022. Procedural and clinical outcomes up to one year were analyzed using Valve Academic Research Consortium-2 criteria.Results A total of 45 consecutive patients with PNAR underwent transfemoral TAVR with the Venus A-Valve across three participating centers between June 2019 and July 2022. The Mean age was 73.5 ± 5.5 years and 26.7% were female. All the TAVR procedures were performed via transfemoral access without cardiopulmonary bypass. Implantations were successful in 44 cases (97.8%). Only one patient was converted to surgical aortic valve replacement. No patient died intraoperatively. No second valve was implanted. In-hospital mortality rate was 2.3%. The one-year all-cause mortality rate was 4.7% without cardiovascular related death. No patient had moderate or severe paravalvular leakage during follow-up. At one year, the mean pressure gradient was 8.8 ± 0.9 mmHg, and left ventricular ejection fraction increased to 61.5 ± 3.6%.Conclusions This single-center study demonstrated the safety and efficacy of transfemoral TAVR with the Venus A-Valve in the treatment of patients with PNAR.